SCHEDULE 13D/A: 180 Life Sciences CEO Blair Jordan Consolidates Significant Voting Power, Reaching 30.2% Beneficial Ownership

Blair Jordan, CEO of 180 Life Sciences Corp., has significantly increased his beneficial ownership to 30.2% of the company's common stock through a combination of restricted stock grants and new voting agreements with key shareholders.

Summary

• Blair Jordan, CEO of 180 Life Sciences Corp., has filed an Amendment No. 1 to his Schedule 13D, reporting a beneficial ownership of 1,721,166 shares, representing 30.2% of the Issuer's common stock outstanding as of April 30, 2025.
• This ownership includes 160,000 shares of restricted common stock granted to Mr. Jordan under the Issuer's 2022 Omnibus Incentive Plan, with 80,000 shares vesting on January 1, 2026, and the remaining 80,000 shares vesting on December 31, 2026.
• A substantial portion of his beneficial ownership, 1,561,166 shares, is derived from irrevocable voting proxies obtained through voting agreements with other shareholders.
• These voting agreements include 43,166 shares from Dr. James Woody (effective February 5, 2025, until February 5, 2026), 200,000 shares from Dr. Marlene Krauss (effective February 21, 2025, until August 21, 2025), and 1,318,000 shares from Elray Resources, Inc. (effective April 28, 2025, until April 28, 2026).
• Mr. Jordan holds sole voting power over his 160,000 restricted shares and shared voting power over the 1,561,166 shares subject to proxies, but he has no dispositive control or pecuniary interest over the shares held by proxy.
• The stated purpose of the acquisition is for investment, with the possibility of future purchases or dispositions of securities.

Sentiment

Score: 6

Explanation: The filing indicates a consolidation of voting power by the CEO, which can be viewed positively for stability and alignment of interests. However, the temporary nature of some voting agreements and the lack of broader financial or operational updates keep the sentiment from being strongly positive.

Positives

• Increased alignment of interests between the CEO and the company's strategic direction due to significant beneficial ownership.
• Consolidation of voting power by the CEO may provide greater stability in corporate governance and decision-making.
• The grant of restricted stock to the CEO indicates a commitment to long-term retention and performance incentives.

Negatives

• The concentration of voting power in the hands of a single individual, even the CEO, could potentially reduce the influence of other shareholders in certain corporate matters.
• The voting agreements are temporary, with varying expiration dates, which could lead to future shifts in voting control.

Risks

• The voting agreements are time-limited, with the earliest expiring on August 21, 2025 (Dr. Krauss's shares), which could lead to a reduction in Mr. Jordan's shared voting power if not renewed or replaced.
• While Mr. Jordan states no current plans for major corporate changes, he retains the right to modify his investment intent and formulate plans that could result in such events, subject to applicable laws.

Future Outlook

The Reporting Person acquired the securities for investment purposes and may purchase additional securities or dispose of existing ones in the future, depending on market conditions and other factors. While no current plans for extraordinary corporate transactions or changes in the company's structure are in place, the Reporting Person retains the right to modify his investment intent and formulate such plans in his capacity as CEO and Board member, subject to applicable laws and regulations.

Management Comments

• "The Reporting Person acquired the securities for investment purposes."
• "The Reporting Person does not currently have any plans or proposals which relate to or would result in... [various corporate actions]."
• "The Reporting Person retains the right to change his investment intent, and may, from time to time, acquire additional shares of Common Stock or other securities of the Company, or sell or otherwise dispose of... all or part of the shares... beneficially owned by him, in any manner permitted by law."
• "However, the Reporting Person, in his capacity as a member of the Board and Chief Executive Officer may, from time to time, become aware of, initiate, and/or be involved in discussions that relate to the transactions described in this Item 4 and thus retains his right to modify his plans with respect to the transactions described in this Item 4 to acquire or dispose of securities of the Company and to formulate plans and proposals that could result in the occurrence of any such events, subject to applicable laws and regulations."

Industry Context

This Schedule 13D filing primarily concerns changes in beneficial ownership and voting control within 180 Life Sciences Corp. and does not provide information directly related to broader industry trends or competitive landscape. It reflects an internal corporate governance and ownership consolidation event rather than a market-wide or sector-specific development.

Corporate Governance

Legal Proceedings

• The Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• The Reporting Person has not been party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws, during the last five years.

Related Party Transactions

• Executive Consulting Agreement dated February 21, 2025, between the Issuer and Blair Jordan Strategy and Finance Consulting Inc. (an entity owned by Mr. Jordan), under which Mr. Jordan was granted 160,000 restricted common shares.

Stakeholder Impact

• Shareholders: The consolidation of voting power by the CEO may reduce the influence of other individual shareholders on matters subject to the voting agreements. However, it could also be seen as a positive for stability and management alignment.
• Management/Employees: The CEO's increased stake and long-term incentive grant (restricted stock) suggest a strong commitment to the company's future.

Next Steps

• Vesting of 80,000 restricted shares on January 1, 2026.
• Vesting of another 80,000 restricted shares on December 31, 2026.
• Potential future purchases or dispositions of securities by the Reporting Person.
• Expiration of voting agreements with Dr. Marlene Krauss (August 21, 2025), Dr. James Woody (February 5, 2026), and Elray Resources, Inc. (April 28, 2026).

Key Dates

Keywords

180 Life Sciences Corp., Blair Jordan, Schedule 13D, Beneficial Ownership, Voting Agreement, Restricted Stock, Corporate Governance, SEC Filing, Insider Ownership, Common Stock